Menu
Search
|

Menu

Close
X

Sun Pharmaceutical Industries Ltd SUN.NS (National Stock Exchange of India)

569.65 INR
+28.20 (+5.21%)
As of Feb 23
chart
Previous Close 541.45
Open 550.00
Volume 30,844,893
3m Avg Volume 5,597,172
Today’s High 575.25
Today’s Low 546.00
52 Week High 729.05
52 Week Low 432.70
Shares Outstanding (mil) 2,399.31
Market Capitalization (mil) 1,366,767.00
Forward P/E 53.11
Dividend (Yield %) 3.50 ( 0.61 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.82 Mean rating from 38 analysts

KEY STATS

Revenue (mm, INR)
FY18
195,124
FY17
316,140
FY16
284,870
FY15
273,920
EPS (INR)
FY18
5.661
FY17
28.946
FY16
18.921
FY15
20.231
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
53.11
33.62
Price to Sales (TTM)
vs sector
5.12
8.35
Price to Book (MRQ)
vs sector
--
5.22
Price to Cash Flow (TTM)
vs sector
31.63
25.88
Total Debt to Equity (MRQ)
vs sector
--
15.84
LT Debt to Equity (MRQ)
vs sector
--
12.39
Return on Investment (TTM)
vs sector
--
13.63
Return on Equity (TTM)
vs sector
--
15.39

EXECUTIVE LEADERSHIP

Israel Makov
Non-Executive Chairman of the Board, Since 2012
Salary: --
Bonus: --
C. Muralidharan
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Sunil Ajmera
Compliance Officer, Company Secretary, Since 2011
Salary: --
Bonus: --
Dilip Shanghvi
Managing Director, Executive Director, Since 2012
Salary: Rs27,990,000.00
Bonus: --
Sailesh Desai
Whole-time Director, Since 1999
Salary: Rs9,867,000.00
Bonus: Rs1,973,400.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Acme Plaza
Andheri Kurla Road, Andheri East
MUMBAI     400 093

Phone: +9122.43244324

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.

SPONSORED STORIES